FUELING THE FUTURE OF EPILEPSY

Epilepsy key facts

For more than 30 years, we have provided solutions that have helped transform the epilepsy landscape and improved the lives of millions of people.

Our scientists have developed several life-changing solutions, providing individualized treatments to help people living with epilepsy.

- **1992**: Discovery and development of levetiracetam
- **2000**: First launch of levetiracetam
- **2008**: First launch of lacosamide
- **2016**: First launch of brivaracetam
- **2019**: First launch of midazolam

Our medicines are taken by ~3 million people living with epilepsy.

UCB has a wealth of experience in epilepsy drug development (>100 interventional epilepsy studies conducted).

OUR COMMITMENT

We are driven to improve the lives of people living with epilepsy, striving for symptom freedom today, anti-epileptogenic options tomorrow

HOW WILL WE ACHIEVE THIS?

Transformative medicine:
- Utilizing our experience and expertise, our transformative science will lead to new treatment options that address specific unmet needs, and one day, solutions that could even impact the underlying causes of the disease
- Several early-stage assets in the pipeline and a number of patient populations under assessment in our internal epilepsy ‘incubator’
- By targeting a prototype of sub-populations, which are both identifiable and sizeable, we will develop a focused strategy to address specific unmet needs of people living with a variety of epilepsies

Health technology support:
Our long-term goal is to improve the detection, management and treatment of seizures, and we see digital health technology as a key component of epilepsy treatment and care. Our current investments and partnerships include:
- Nile AI: Digital care management platform to improve the coordination of all stakeholders in epilepsy care
- Byteflies: Commercialization of a seizure detection device
- Helpilepsy: A digital solution that integrates information for both patients and neurologists to manage their disease and improve patient outcomes
- Neuro Event Labs: A smart solution for seizure detection, combining artificial intelligence and human expertise

Sustainable value:
Over the next 5 years we will bring UCB’s epilepsy treatments to more patients than ever before:
- Potential solutions for unmet needs: Delivery of an investigational new product as a potential solution for the rapid cessation of an ongoing seizure in patients with stereotypical prolonged seizures
- Building partnerships: To co-create evidence that demonstrates the value of treatments; with payers on value based contracts; and with hospitals on research projects that aim to improve care pathways and patient outcomes
- Equitable access: We are providing improved access to quality care and medicines in low to medium income countries, through social business approaches

To learn more about UCB’s commitment to epilepsy, visit www.ucb.com/UCBCares

References:

© UCB Biopharma SRL, 2021. All rights reserved.

Transformative science
Potential solutions for unmet needs
Value based contracts
Social business approaches